TRPM2 and early-onset autosomal dominant Alzheimer disease: Studies have demonstrated that TRPM2 contributes to neurodegeneration and inflammatory processes in Alzheimer's disease, ischemia, multiple sclerosis, and epilepsy (Huang et al. 2017; Jiang et al. 2018; Shao et al. 2021; Tsutsui et al. 2018; Zong et al. 2022), suggesting TRPM2 as a promising therapeutic target.